论文部分内容阅读
目的:探讨脑小血管病(cerebral small vascular disease，CSVD)患者血清基质金属蛋白酶9(matrix metalloproteinase-9，MMP-9)水平与非痴呆性血管性认知功能障碍(vascular cognitive impairment with no dementia，VCIND)的相关性。方法:收集2016年1月至2020年1月新乡医学院第一附属医院神经内科收治的374例CSVD患者，及同期150例健康体检者作为对照组。所有受试者均采用酶联免疫吸附法检测血清MMP-9水平，蒙特利尔认知评估量表(Montreal cognitive assessment，MoCA)进行认知功能评分。374例CSVD患者分为非痴呆性血管性认知功能障碍组(A组，n n＝186)和无认知障碍组(B组，n n＝188)，比较三组间一般资料、血清MMP-9水平、认知功能评分，并分析MMP-9水平与认知功能的相关性。n 结果:A组和B组MMP-9水平[(335.10±105.10)μg/L，(261.62±80.32)μg/L]均高于对照组[(168.23±48.85)μg/L]，且A组的MMP-9水平高于B组(n P<0.05)。A组和B组MoCA评分[(18.45±5.24)分，(28.31±1.52)分]均低于对照组[(29.49±0.90)分]，且A组的MoCA评分低于B组(n P<0.05)。血清MMP-9水平是CSVD患者VCIND的危险因素(n β＝1.505，n OR＝ 1.323，95%n CI＝1.149～1.527，n P<0.05)，与MoCA量表总分、视空间与执行功能、命名、语言、抽象思维、延迟回忆、定向力呈负相关(相关系数分别为n r＝-0.299、n r＝-0.155、n r＝-0.383、n r＝-0.358、n r＝-0.192、n r＝-0.259、n r＝-0.246，均n P<0.05)。n 结论:血清MMP-9水平升高可能是CSVD患者非痴呆性血管性认知功能障碍的危险因素，且与患者认知功能有一定的相关性。“,”Objective:To investigate the relationship between serum matrix metalloproteinase-9(MMP-9) level and vascular cognitive impairment with no dementia (VCIND) in patients with cerebral small vessel diseases (CSVD).Methods:A total of 374 patients with CSVD treated in the First Affiliated Hospital of Xinxiang Medical University from January 2016 to January 2020 were collected and 150 healthy subjects in the same period were used as general data of the control group. All subjects were detected for serum MMP-9 level using enzyme linked immunosorbent assay and received cognitive function scoring using Montreal cognitive assessment (MoCA). The 374 patients with CSVD were divided into the Group A(186 cases with vascular cognitive impairment with no dementia) and the Group B(188 cases without cognitive impairment). The general data, serum MMP-9 level and cognitive function score were compared among the three groups and the correlation between MMP-9 level and cognitive function was analyzed.Results:The MMP-9 levels of Groups A and B ( (335.10±105.10)μg/L, (261.62±80.32)μg/L) were higher than those of the control group ( (168.23±48.85)μg/L), and the MMP-9 level of Group A was higher than that of Group B (n P<0.05). The MoCA scores of Groups A and B ( (18.45±5.24), (28.31±1.52) ) were lower than those of the control group (29.49±0.90), and the MoCA scores of Group A were lower than those of Group B (n P<0.05). The serum MMP-9 level, a risk factor for VCIND in patients with CSVD (n β=1.505, n OR=1.323, 95%n CI=1.149-1.527, n P<0.05), was negatively correlated with total score of MoCA scale, visual-spatial and executive function, naming, language, abstract thinking, delayed recall, and directive force factor score (n r=-0.299, n r=-0.155, n r=-0.383, n r=-0.358, n r=-0.192, n r=-0.259, n r=-0.246 respectively, all n P<0.05).n Conclusion:The increased level of MMP-9 may be a risk factor of VCIND in CSVD patients, and it is closely related to cognitive impairment.